611 related articles for article (PubMed ID: 26245865)
1. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
2. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
3. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
4. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
[TBL] [Abstract][Full Text] [Related]
5. The Rhode Island community responds to opioid overdose deaths.
Bowman S; Engelman A; Koziol J; Mahoney L; Maxwell C; McKenzie M
R I Med J (2013); 2014 Oct; 97(10):34-7. PubMed ID: 25271658
[TBL] [Abstract][Full Text] [Related]
6. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
7. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
[TBL] [Abstract][Full Text] [Related]
8. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
9. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
10. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
[TBL] [Abstract][Full Text] [Related]
11. Emergency department naloxone distribution: a Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths.
Samuels E
R I Med J (2013); 2014 Oct; 97(10):38-9. PubMed ID: 25271659
[TBL] [Abstract][Full Text] [Related]
12. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
[TBL] [Abstract][Full Text] [Related]
13. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
14. Vital Signs: Pharmacy-Based Naloxone Dispensing - United States, 2012-2018.
Guy GP; Haegerich TM; Evans ME; Losby JL; Young R; Jones CM
MMWR Morb Mortal Wkly Rep; 2019 Aug; 68(31):679-686. PubMed ID: 31393863
[TBL] [Abstract][Full Text] [Related]
15. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
16. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
17. The changing landscape of naloxone availability in the United States, 2011 - 2017.
Freeman PR; Hankosky ER; Lofwall MR; Talbert JC
Drug Alcohol Depend; 2018 Oct; 191():361-364. PubMed ID: 30195192
[TBL] [Abstract][Full Text] [Related]
18. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
19. Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?
Wunderlich JR; Engelberg RS; Tofighi B; Schwartz MD
J Gen Intern Med; 2022 Aug; 37(11):2621-2623. PubMed ID: 35581455
[No Abstract] [Full Text] [Related]
20. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]